Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma

An announcement from Oncopeptides AB ( (SE:ONCO) ) is now available.

Oncopeptides AB reported new real-world data from an Italian center showing that Pepaxti, combined with dexamethasone, achieved a 41% overall response rate and a median progression-free survival of nine months in heavily pretreated, relapsed or refractory multiple myeloma patients, many of whom were elderly and highly treatment resistant. The study also indicated Pepaxti’s manageable safety profile in frail populations and suggested it can be strategically used as a bridging therapy, as all patients proceeding to subsequent novel immunotherapies such as CAR-T or bispecific antibodies achieved at least a partial response, reinforcing Pepaxti’s role in treatment sequencing and supporting Oncopeptides’ ongoing commercial rollout in Italy and across Europe.

The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.

More about Oncopeptides AB

Oncopeptides AB is a Swedish biotech company specializing in targeted therapies for difficult-to-treat cancers, leveraging its proprietary Peptide Drug Conjugate and SPiKE platforms to deliver cytotoxic agents selectively into cancer cells. The company’s flagship drug Pepaxti is being commercialized across Europe with additional partnership agreements in regions including South Korea, the Middle East and Africa, supported by operations in several EU markets and a listing on Nasdaq Stockholm under the ticker ONCO.

Average Trading Volume: 2,251,689

Technical Sentiment Signal: Sell

Current Market Cap: SEK648.5M

Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.